2005
DOI: 10.1016/j.mam.2005.01.004
|View full text |Cite
|
Sign up to set email alerts
|

Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
46
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 106 publications
(48 citation statements)
references
References 130 publications
1
46
1
Order By: Relevance
“…However, there is evidence in literature that frailty and osteoporosis (consequence of low BMD) share risk factors (age group, sarcopenia, sedentarism, low body weight, consumption of tobacco) and physiopathological mechanisms [27,28]. In the latter, alterations in estrogen and growth hormone levels would be related to osteoporosis, as these are involved in the bone remodeling process, and related to frailty because they contribute with loss of muscle mass and strength [27,29,30]. This information presents biological plausibility as in this study, loss of strength in women was the frailty component associated with low BMD.…”
Section: Discussionmentioning
confidence: 99%
“…However, there is evidence in literature that frailty and osteoporosis (consequence of low BMD) share risk factors (age group, sarcopenia, sedentarism, low body weight, consumption of tobacco) and physiopathological mechanisms [27,28]. In the latter, alterations in estrogen and growth hormone levels would be related to osteoporosis, as these are involved in the bone remodeling process, and related to frailty because they contribute with loss of muscle mass and strength [27,29,30]. This information presents biological plausibility as in this study, loss of strength in women was the frailty component associated with low BMD.…”
Section: Discussionmentioning
confidence: 99%
“…These common age-related changes in skeletal muscle are major causes of impaired physical function in older adults, contributing to impaired mobility, falls and hospitalisation. The causes of sarcopenia are multifactorial and can include muscle disuse, changing endocrine function, chronic diseases, inflammation, insulin resistance and nutritional deficiencies [38]; reductions in testosterone and oestrogen that accompany ageing appear to accelerate its development [39].…”
Section: Sarcopeniamentioning
confidence: 99%
“…First, there are a number of individual physiologic systems that have been identified as dysregulated in association with frailty. As background, there are many data that indicate declines with age in function of multiple functional and regulatory systems in the body, such as circulating levels of specific hormones (e.g., estrogens, testosterone, and insulin-like growth factor 1 [IGF-1]) (Kuchel et al 2001), impaired insulin sensitivity (Davidson 1979;DeFronzo 1981;Shimokata et al 1991;Scheen 2005;Metter et al 2008), along with elevations of markers of inflammation (e.g., interleukin 6 [IL-6] and C-reactive protein [CRP]) with aging (Ershler and Keller 2000;Reuben et al 2002;Cohen et al 2003;Joseph et al 2005). Dynamic interactions between declines in gonadal hormones and increases in inflammatory mediators affect bone mass, as well as mobility (Cappola et al 2003), whereas the impaired insulin sensitivity is predictive of both frailty and diabetes (Kalyani et al 2012b).…”
Section: Mechanisms Underlying the Clinical Syndrome Of Frailtymentioning
confidence: 99%
“…For example, sarcopenia results, in part, both from hormonal deficiency and cytokine excess Morley et al 2005). Postmenopausal declines in serum estrogen and androgen levels contribute to increased bone loss (Joseph et al 2005). Higher serum testosterone in older women is associated with insulin resistance (IR) and metabolic syndrome (Patel et al 2009).…”
Section: Mechanisms Underlying the Clinical Syndrome Of Frailtymentioning
confidence: 99%
See 1 more Smart Citation